Biogen (BIIB) News Today

Biogen Inc. (NASDAQ: BIIB) — shares are trading higher after a wave of analyst model updates from Wedbush that lift near‑term and multi‑year EPS forecasts, offset by a retained "Neutral" rating and a price target below the market. Below are the key items investors should know and the likely directional drivers.

• Positive Sentiment: Wedbush raised multiple quarterly and longer‑term EPS estimates (Q1/Q2/Q3 and several FY years), signaling better‑than‑expected profit outlooks that support the stock’s lift; Wedbush expects Q1 2027 EPS of $4.13, Q2 2027 $4.67 and Q3 2027 $4.34, and raised FY2026–FY2029 estimates. Wedbush Has Optimistic Outlook of Biogen Q1 Earnings
• Neutral Sentiment: Despite the estimate lifts, Wedbush kept a "Neutral" rating and a $135 price target — a restraint on upside since the PT is below the current market price and may limit analyst‑driven buying. Wedbush Comments on Biogen's FY2025 Earnings
• Neutral Sentiment: Corporate/industry items with unclear impact include coverage of biogenic CO2 opportunities and a separate report about a Hong Kong‑listed "Giant Biogene" shareholder stake (different company), neither of which appear likely to move BIIB materially. Green Plains And Biogenic CO2 Giant Biogene’s Controlling Shareholder Increases Stake
• Negative Sentiment: Wedbush trimmed its FY2025 EPS view slightly (to ~$15.66) and an AmericanBankingNews piece flagged a more pessimistic Wedbush take — these downwards tweaks and negative headlines can weigh sentiment, especially given the maintained Neutral rating. Wedbush Issues Pessimistic Estimate for Biogen Earnings
• Negative Sentiment: Broader negative commentary highlighting risks in BIIB’s profile (valuation, product or regulatory concerns) surfaced in a syndicated “3 Reasons BIIB is Risky” piece; such narratives can amplify volatility and selling pressure if investors focus on downside. 3 Reasons BIIB is Risky and 1 Stock to Buy Instead

Bottom line for investors: upgraded EPS modeling is the main positive catalyst supporting today’s move, but the neutral analyst stance and lower near‑term/negative coverage items limit conviction — watch upcoming earnings, guidance, and whether analysts convert estimate upgrades into higher price targets.